Loading organizations...

Palvella Therapeutics is a technology company.
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies. It specifically targets serious, rare genetic dermatological diseases, addressing conditions with significant unmet medical needs. The company's approach advances a pipeline of treatments, improving patient outcomes in these underserved populations.
Founded by Wesley Kaupinen, Palvella Therapeutics leverages his extensive experience in life sciences and rare disease drug development. Kaupinen’s vision was to address the critical need for dedicated solutions in rare genetic dermatological conditions, an insight guiding the company's strategic focus. This leadership background reflects a deep understanding of specialized therapeutic markets.
The company serves patients afflicted by serious, rare genetic skin diseases, striving to provide effective treatment options where few alternatives exist. Palvella Therapeutics' mission is to deliver transformative medicines, establishing itself as a leader in this therapeutic area. It remains committed to developing and commercializing therapies that significantly impact patients.
Palvella Therapeutics has raised $82.7M across 2 funding rounds.
Palvella Therapeutics has raised $82.7M in total across 2 funding rounds.
Palvella Therapeutics has raised $82.7M in total across 2 funding rounds.
Palvella Therapeutics's investors include Gore Range Capital, Tadd S. Wessel, Agent Capital, BioAdvance, BVF Partners, Nolan Capital, Samsara BioCapital, Adams Street Partners, Scott Morenstein, Ligand Pharmaceuticals, Sean Nolan, Opaleye Management.
Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing novel therapies for serious, rare skin diseases lacking FDA-approved treatments.[1][2] It builds a pipeline based on its patented QTORIN™ platform, with the lead candidate QTORIN™ 3.9% rapamycin anhydrous gel advancing in Phase 3 (SELVA trial for microcystic lymphatic malformations) and Phase 2 (TOIVA trial for cutaneous venous malformations).[1] The company serves patients with lifelong rare dermatological conditions and their physicians, addressing unmet needs where no approved therapies exist, while demonstrating growth through public listing and ongoing clinical momentum.[1][2][3]
Founded and led by rare disease experts, Palvella aims to become the leading player in this niche by expanding options via its topical rapamycin-based innovations.[2]
Palvella Therapeutics was founded by veterans in rare disease drug development, though specific founding year details are not specified in available sources.[1] The company's emergence stems from recognizing gaps in treatments for serious rare skin diseases, leading to the creation of the patented QTORIN™ platform—a topical formulation of rapamycin designed for dermatological applications.[1][2] Early pivotal moments include advancing its lead asset into late-stage trials: the Phase 3 SELVA study and Phase 2 TOIVA study, marking progression as a publicly-traded entity (Nasdaq: PVLA).[1][3] Leadership and advisory boards feature prominent experts like Keith Choate (Yale), Amy S. Paller (Northwestern), and Joyce Teng (Stanford), humanizing its mission-driven focus on patient needs.[2]
Palvella rides the wave of precision medicine in rare diseases, particularly dermatology, where genetic insights and targeted topicals address unmet needs in orphan indications.[1][2] Timing aligns with rising investment in biopharma pipelines for niche markets, fueled by FDA incentives like orphan drug designations and accelerated approvals. Market forces favoring Palvella include growing recognition of rapamycin's potential in vascular skin malformations and a shortage of approved therapies, enabling it to influence the ecosystem by pioneering topical formulations that could set standards for similar conditions.[1] As a public clinical-stage player, it contributes to biotech innovation in Pennsylvania's life sciences hub.[1][3]
Palvella's trajectory hinges on readout from the Phase 3 SELVA and Phase 2 TOIVA trials, potentially unlocking FDA submissions and first approvals in rare skin diseases.[1] Trends like expanded rapamycin applications and rare disease funding will shape its path, with pipeline growth via the QTORIN™ platform driving expansion. Its influence may evolve from niche innovator to category leader, delivering on the vision of abundant options for patients—transforming a landscape of unmet needs into one of viable therapies.[2]
Palvella Therapeutics has raised $82.7M across 2 funding rounds. Most recently, it raised $37.7M Series D in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 9, 2023 | $37.7M Series D | Gore Range Capital, Tadd S. Wessel | Agent Capital, BioAdvance, BVF Partners, Nolan Capital, Samsara BioCapital |
| May 1, 2020 | $45.0M Series C | Samsara BioCapital, Adams Street Partners, Agent Capital, BioAdvance, BVF Partners, Scott Morenstein, Ligand Pharmaceuticals, Sean Nolan, Opaleye Management |